Literature DB >> 2434352

Evidence for immunosuppression by high-dose gammaglobulin.

K Kawada, P I Terasaki.   

Abstract

High-dose immunoglobulin therapy, which is useful for the treatment of idiopathic thrombocytopenic purpura, autoimmune neutropenia, childhood epilepsy, and Kawasaki disease is postulated here to act by immunosuppressing the patients. Evidence provided here shows that the immunoglobulin inhibits phytohemagglutinin (PHA) stimulation, mixed lymphocyte culture (MLC) response, natural killer assay, antibody-dependent cell-mediated cytotoxicity, and cell-mediated lympholysis. These assays were all inhibited by IgG concentrations that exceeded normal levels by 1.5-2 times. It is also shown that Fc fragments were 100-1000 times more effective than intact IgG in inhibiting the PHA and MLC responses. Thus, it is likely that the Fc portion of immunoglobulin functions as an inhibitor of cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434352

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  Natural antibody-induced intracellular signalling and growth control in C3H 10T1/2 fibroblast variants.

Authors:  H Wang; D A Chow
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

Authors:  D Nachbaur; M Herold; B Eibl; H Glassl; H Schwaighofer; C Huber; A Gächter; M Pichl; D Niederwieser
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

4.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

Review 5.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 6.  The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases.

Authors:  D Y Leung
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

7.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 8.  Mechanism of action of intravenous immunoglobulin in immune-mediated cytopenias.

Authors:  H I Atrah; R J Davidson
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

Review 9.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

10.  Poliomyelitis-like syndrome following asthmatic attack (Hopkins' syndrome)--recovery associated with i.v. gamma globulin treatment.

Authors:  H A Cohen; A Ashkenasi; H Ring; R Weiss; B Wolach; G Paret; A Barzilai
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.